Variables | Training set (n = 160) | P | Validation set (n = 66) | P | ||
---|---|---|---|---|---|---|
CR | Non-CR | CR | Non-CR | |||
Age (years), mean ± SD | 66.18 ± 9.55 | 64.55 ± 10.56 | 0.337 | 65.64 ± 10.09 | 66.48 ± 8.88 | 0.730 |
Gender | 0.064 | 0.258 | ||||
Male | 36 (30.8) | 81 (69.2) | 15 (31.2) | 33 (68.8) | ||
Female | 20 (46.5) | 23 (53.5) | 7 (38.9) | 11 (61.1) | ||
Tumor location | 0.221 | 0.216 | ||||
Cervical | 4 (40.0) | 6 (60.0) | 2 (50) | 2 (50) | ||
Upper thoracic | 16 (41.0) | 23 (59.0) | 6 (50) | 6 (50) | ||
Middle thoracic | 32 (36.8) | 55 (63.2) | 13 (32.5) | 27 (67.5) | ||
Lower thoracic | 4 (16.7) | 20 (83.3) | 1 (50%) | 1 (50%) | ||
Clinical stage | < 0.001 | 0.016 | ||||
I | 1 (100.0) | 0 (0) | 1 (100.0) | 0 (0) | ||
II | 12 (70.6) | 5 (29.4) | 5 (50.0) | 5 (50.0) | ||
III | 40 (43.5) | 52 (56.5) | 14 (42.4) | 19 (57.6) | ||
Iva | 3 (6.0) | 47 (94.0) | 2 (9.1) | 44 (90.9) | ||
Radiation dose, median (range) | 64 (61.25–66) | 64 (62–66) | 0.221 | 63 (60–65.75) | 63 (60–65.75) | 0.737 |
Chemotherapy regimen | 0.209 | 0.831 | ||||
PF | 43 (38.1) | 70 (61.9) | 17 (32.7) | 35 (67.3) | ||
TP | 13 (27.7) | 34 (72.3) | 5 (35.7) | 9 (65.3) | ||
LDH | 0.226 | 0.587 | ||||
High | 24 (30.4) | 55 (69.6) | 7 (29.2) | 17 (70.8) | ||
Normal | 32 (39.5) | 49 (60.5) | 15 (35.7) | 27 (65.3) | ||
NLR, median (range) | 2.59 (1.72–3.14) | 2.87 (2.01–3.99) | 0.033 | 2.80 (1.88–3.58) | 2.9 (1.56-.3.90) | 0.935 |
PLR, median (range) | 128 (100.20–160.47) | 139.74 (103.63–181.40) | 0.158 | 127.37 (95.64–192.44) | 148.26 (94.90–197.13) | 0.924 |
Rad-score, mean ± SD | − 13.39 ± 3.39 | − 17.58 ± 3.58 | < 0.001 | − 13.87 ± 3.30 | − 16.81 ± 3.51 | < 0.001 |